High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: A prospective, clinical and histological 10-year follow-up study

British Journal of Dermatology

Volumn 166, Issue 6, 2012, Pages 1342-1348

  Christensen, E ^a   Mork C ^b   Skogvoll, E ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; DIMETHYL SULFOXIDE;

ADULT; AGED; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG TREATMENT FAILURE; ESTHETICS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT CANCER; REVIEW; SKIN EXAMINATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; CURETTAGE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84861584933     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10878.x     Document Type: Review

References (35)

1. Miller DL, Weinstock MA,. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30: 774-8.
2. Crowson AN,. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006; 19 (Suppl. 2): S127-47.
3. Bath-Hextall FJ, Perkins W, Bong J, Williams HC,. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007; 1: CD003412.
4. Szeimies RM,. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatol Clin 2007; 25: 89-94.
5. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007; 143: 1131-6.
6. Morton CA, McKenna KE, Rhodes LE,. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008; 159: 1245-66.
7. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79: 2282-308.
8. Kennedy JC, Pottier RH, Pross DC,. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990; 6: 143-8.
9. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007; 56: 125-43.
10. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18: 547-53.
11. Souza CS, Felicio LB, Ferreira J, et al. Long-term follow-up of topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for non-melanoma skin cancer. Photodiagnosis Photodyn Ther 2009; 6: 207-13.
12. Gerritsen MJ, Smits T, Kleinpenning MM, et al. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009; 218: 193-202.
13. Sandberg C, Halldin CB, Ericson MB, et al. Bioavailability of aminolaevulinic acid and methylaminolaevulinate in basal cell carcinomas: a perfusion study using microdialysis in vivo. Br J Dermatol 2008; 159: 1170-6.
14. Warloe T, Heyerdahl H, Giercksky KE,. Curettage and Topical ALA-based Photodynamic Therapy for Nodular Basal Cell Carcinoma. PhD Thesis, University of Oslo, 1995; paper VI.
15. Christensen E, Skogvoll E, Viset T, et al. Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up. J Eur Acad Dermatol Venereol 2009; 23: 58-66.
16. Rowe DE, Carroll RJ, Day CL Jr,. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15: 315-28.
17. Rowe DE, Carroll RJ, Day CL Jr,. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989; 15: 424-31.
18. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 2008; 18: 677-82.
19. Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 1: overview. J Dermatol Surg Oncol 1991; 17: 713-18.
20. R Development Core Team. The R Project for Statistical Computing, 2010. Available at: (last accessed 20 February 2012).
21. Thissen MR, Neumann MH, Schouten LJ,. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177-83.
22. Fantini F, Greco A, Del Giovane C, et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol 2011; 25: 896-901.
23. Farhadi M, Kamrava SK, Behzadi AH, et al. The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma. J Drugs Dermatol 2010; 9: 122-6.
24. Ramachandran S, Fryer AA, Lovatt TJ, et al. Combined effects of gender, skin type and polymorphic genes on clinical phenotype: use of rate of increase in numbers of basal cell carcinomas as a model system. Cancer Lett 2003; 189: 175-81.
25. Batra RS, Kelley LC,. A risk scale for predicting extensive subclinical spread of nonmelanoma skin cancer. Dermatol Surg 2002; 28: 107-12.
26. Takenouchi T, Nomoto S, Ito M,. Factors influencing the linear depth of invasion of primary basal cell carcinoma. Dermatol Surg 2001; 27: 393-6.
27. Rigel DS, Robins P, Friedman RJ,. Predicting recurrence of basal-cell carcinomas treated by microscopically controlled excision: a recurrence index score. J Dermatol Surg Oncol 1981; 7: 807-10.
28. Mazeron JJ, Chassagne D, Crook J, et al. Radiation therapy of carcinomas of the skin of nose and nasal vestibule: a report of 1676 cases by the Groupe Européen de Curietherapie. Radiother Oncol 1988; 13: 165-73.
29. Vinciullo C, Elliott T, Francis D, et al. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol 2005; 152: 765-72.
30. Mosterd K, Thissen MR, Nelemans P, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 2008; 159: 864-70.
31. Peng Q, Soler AM, Warloe T, et al. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol, B 2001; 62: 140-5.
32. Malik Z, Kostenich G, Roitman L, et al. Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of mice. J Photochem Photobiol B 1995; 28: 213-18.
33. Warloe T, Peng Q, Heyerdahl H, et al. Photodynamic therapy with 5-aminolevulinic acid-induced porphyrins and DMSO/EDTA for basal cell carcinoma. Proc SPIE 1994; 2371: 226-35.
34. Cigna E, Tarallo M, Maruccia M, et al. Basal cell carcinoma: 10 years of experience. J Skin Cancer 2011; 2011: 476362.
35. Christensen E, Warloe T, Kroon S, et al. Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2010; 24: 505-12.